Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer

University of New Mexico

Overview

The Tissue Repository will search for cases, pull slides, Paraffin-embedded tissue (PET) blocks.

This study is done to gather preliminary data for determining the best way to test EGFR expression in patients with cervical cancer who will receive treatment with EGFR inhibitors in the future. This study is designed to obtain preliminary data of genomic and phenotypic alterations of the EGFR pathway in high grade cervical intraepithelial lesions (HG-SIL) and invasive cervical cancers (CC) to be used later for therapeutic guidance and to evaluate genomic (over-expression, amplification, point mutations, etc.) and phenotypic alterations of other transduction pathways interacting with the EGFR pathway.

Study Type

INTERVENTIONAL

Conditions

Cervical Cancer Cervix

Interventions

Tissue RepositoryGENETIC

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: * Samples from patients diagnosed with HG-SIL (n=300) and CC (n=300) with a follow-up of at least 24 months, existing at the Department of Pathology will be retrieved by the Tissue Repository, de-identified them and provided with code numbers that will not be linked to patient's data. Exclusion Criteria: * None Specified.

Locations (1)

University of New Mexico

Albuquerque, New Mexico, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.